<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982966</url>
  </required_header>
  <id_info>
    <org_study_id>omega 3 fatty acids on CRF</org_study_id>
    <nct_id>NCT03982966</nct_id>
  </id_info>
  <brief_title>Effect of Omega 3 Fatty Acids on the Vascular Calcification Biomarkers Fetuin A and Osteoprotegerin in Patients With CRF</brief_title>
  <acronym>CRF</acronym>
  <official_title>The Effect of the of Omega 3 Fatty Acids on the Vascular Calcification Biomarkers Fetuin A and Osteoprotegerin in Patients With Chronic Renal Failure Undergoing Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      study the effect of omega 3fatty acids on the vascular calcification biomarkers Fetuin -A and
      Osteoprotegerin (OPG) in dialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2-All Participants agreed to take part in this clinical research and provide informed
      consent.

      3-Patients undergo both undergo hemodialysis (HD) will be enrolled from dialysis unit in al
      Moussa Hospital Alexandria.

      4-Serum samples will be collected for measuring the biomarkers. 5-Our design is randomized,
      controlled, open-intervention study. 6- All enrolled patients will be divided into 2 groups,
      Group 1 will be 40 patients that will take omega 3fatty acids and Group 2 will be 20 patients
      will not take omega 3 fatty acids.

      7-All patients will be followed up during 6 months' period. 8-Statsicial tests appropriate to
      the study design will be conducted to evaluate the significance of the results.

      9-Measuring outcome: the primary outcome is the increase of the serum levels of the vascular
      calcification biomarkers after 6months.

      10-Results, conclusions, discussion and recommendations will be given.

      Inclusion criteria:

        -  60 hemodialysis patients, (20-80) years old.

        -  Enrolled HD patients received regular HD 3 times weekly (on chronic maintenance for at
           least 6months).

      Exclusion Criteria:

      People with active infections (fever or any evidence of infections), known malignancy,
      connective tissue disorders, immunosuppressive therapy, and inflammatory diseases, current
      use of warfarin ,history of fish oil/omega 3 allergies were excluded.

      Methodology:

        -  Feutin-A and Osteoprotegrin (OPG) will be determined by ELISA.

        -  Serum lipid levels, phosphorus, calcium, Parathormone (i-PTH), alkaline phosphatase,
           albumin and creatine levels.

        -  BMI
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>enrolled patients will be divided into 2 groups, Group 1 will be 40 patients that will take omega 3fatty acids and Group 2 will be 20 patients served as control will not take omega 3 fatty acids.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feutin-A Level</measure>
    <time_frame>six months</time_frame>
    <description>vascular calcification biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegrin</measure>
    <time_frame>six months</time_frame>
    <description>vascular calcification biomarkers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Omega 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 patients will not take omega 3 fatty acids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 fatty acids (fish oil) 1000 mg/day oral</intervention_name>
    <description>Omega 3 fatty acids (fish oil) 1000 mg/day oral</description>
    <arm_group_label>Omega 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 hemodialysis patients, (20-80) years old.

          -  Enrolled HD patients received regular HD 3 times weekly (on chronic maintenance for at
             least 6 months).

        Exclusion Criteria:

          -  People with active infections (fever or any evidence of infections), known malignancy,
             connective tissue disorders, immunosuppressive therapy, and inflammatory diseases,
             current use of warfarin ,history of fish oil/omega 3 allergies were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Pharmacy Lecturer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>al Mowassah Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>London GM, Marchais SJ, Guerin AP. Arterial stiffness and function in end-stage renal disease. Adv Chronic Kidney Dis. 2004 Apr;11(2):202-9. Review.</citation>
    <PMID>15216492</PMID>
  </reference>
  <reference>
    <citation>Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009 Oct;24(10):3157-62. doi: 10.1093/ndt/gfp253. Epub 2009 Jun 2.</citation>
    <PMID>19491380</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Clinical Pharmacy Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

